Cargando…
Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer
Cetuximab (Cmab), a chimeric monoclonal antibody for targeting the epidermal growth factor receptor, has become one of the standard treatments for metastatic colorectal cancer (mCRC). However, only a small proportion of patients respond to Cmab, and it has been reported that KRAS mutation is a negat...
Autores principales: | NAKAMOTO, KENTARO, NAGAHARA, HISASHI, MAEDA, KIYOSHI, NODA, EIJI, INOUE, TORU, YASHIRO, MASAKAZU, NISHIGUCHI, YUKIO, OHIRA, MASAICHI, HIRAKAWA, KOSEI |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629210/ https://www.ncbi.nlm.nih.gov/pubmed/23599782 http://dx.doi.org/10.3892/ol.2013.1187 |
Ejemplares similares
-
The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer
por: Shibutani, Masatsune, et al.
Publicado: (2016) -
Clinical significance of the expression of connexin26 in colorectal cancer
por: Nomura, Shinya, et al.
Publicado: (2010) -
The outcome of surgical treatment for elderly patients with gastric carcinoma
por: Sakurai, Katsunobu, et al.
Publicado: (2015) -
Significance of tumor‐infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer
por: Matsutani, Shinji, et al.
Publicado: (2018) -
Verification of the methodology for evaluating tumor-infiltrating lymphocytes in colorectal cancer
por: Matsutani, Shinji, et al.
Publicado: (2018)